| [1] |
Tella SH, Kommalapati A, Borad MJ, et al. Second-line therapies in advanced biliary tract cancers[J]. Lancet Oncol, 2020, 21(1):e29-41.
|
| [2] |
Baiu I, Visser B. Gallbladder cancer[J]. JAMA, 2018, 320(12):1294.
|
| [3] |
Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J]. Cancer Treat Rev, 2020(84):101936.
|
| [4] |
Löffler MW, Chandran PA, Laske K, et al. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient[J]. J Hepatol, 2016, 65(4):849-855.
|
| [5] |
Rahma OE, Hamilton JM, Wojtowicz M, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors[J]. J Transl Med, 2014(12):55.
|
| [6] |
Aruga A, Takeshita N, Kotera Y, et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer[J]. J Transl Med, 2014(12):61.
|
| [7] |
Kaida M, Morita-Hoshi Y, Soeda A, et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer[J].J Immunother, 2011, 34(1):92-99.
|
| [8] |
Chen F, Zou Z, Du J, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors[J]. J Clin Invest, 2019, 129(5):2056-2070.
|
| [9] |
Gouttefangeas C, Rammensee HG. Personalized cancer vaccines: adjuvants are important, too[J]. Cancer Immunol Immunother, 2018, 67(12):1911-1918.
|
| [10] |
van Willigen WW, Bloemendal M, Gerritsen WR, et al. Dendritic cell cancer therapy: vaccinating the right patient at the right time[J]. Front Immunol, 2018(9):2265.
|
| [11] |
Kobayashi M, Sakabe T, Abe H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg, 2013, 17(9):1609-1617.
|
| [12] |
Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: current status and emerging strategies[J]. World J Gastrointest Oncol, 2015, 7(11):338-346.
|
| [13] |
Abe T, Amano H, Shimamoto F, et al. Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy[J]. Eur J Surg Oncol, 2015, 41(11):1515-1521.
|
| [14] |
Jiraviriyakul A, Songjang W, Kaewthet P, et al. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns[J]. World J Gastroenterol, 2019, 25(29):3941-3955.
|
| [15] |
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184):641-645.
|
| [16] |
Janakiram M, Shah UA, Liu W, et al. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3[J]. Immunol Rev, 2017, 276(1):26-39.
|
| [17] |
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy[J]. Science, 2020, 367(6477): eaax0182.
|
| [18] |
Gou M, Zhang Y, Si H, et al. Efficacy and safety of nivolumab for metastatic biliary tract cancer[J]. Onco Targets Ther, 2019(12):861-867.
|
| [19] |
Kang J, Jeong JH, Hwang HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response[J]. Cancer Res Treat, 2020, 52(2):594-603.
|
| [20] |
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations[J]. Front Oncol, 2018(8):86.
|
| [21] |
Zhang P, Xiong X, Rolfo C, et al. Mechanism- and immune landscape-based ranking of therpeutic responsiveness of 22 major human cancers to next generation anti-CTLA-4 antibodies[J]. Cancers, 2020, 12(2):284.
|
| [22] |
Xie C, Duffy AG, Mabry-Hrones D, et al. Tremelimumab in combination with microwave albation in patients with refractory biliary tract cancer[J]. Hepatology, 2019, 69(5):2048-2060.
|
| [23] |
Imaoka Y, Kuranishi F, Miyazaki T, et al. Long-lasting complete response status of advanced stage IV gallbladder cancer and colon cancer after combined treatment including autologous fromalin-fixed tumor vaccine: two case reports[J]. World J Surg Oncol, 2017, 15(1): 170.
|
| [24] |
Pollom EL, Alagappan M, Park LS, et al. Does radiotherapy still have a role in unresected biliary tract cancer?[J]. Cancer Med, 2017, 6(1):129-141.
|
| [25] |
Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547):373-377.
|